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Abstract
Background: Acute kidney injury remains a common complication in critically ill patients and despite multiple trials
and observational studies, the optimal timing for initiation of renal replacement therapy is still unclear. The early
versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury (ELAIN) study is a
randomized, single-center, prospective, two-arm, parallel group trial to reduce mortality in patients with severe
acute kidney injury. We describe the study design and discuss aspects of the need for a trial in this patient cohort.
Methods/design: Our plan is to randomize critically ill patients with acute kidney injury to ‘early’ or ‘late’ initiation
of renal replacement therapy according to stage 2 and 3 of the KDIGO classification using a specific trial protocol.
We plan to guide data collection and analysis using pre-existing definitions and testing. The primary endpoint is
overall survival in a 90-day follow-up period. Secondary endpoints include 28-day, 60-day, 90-day and 1-year all-
cause mortality, recovery of renal function, ICU and hospital length-of-stay. The primary analysis will be an
intention-to-treat analysis; secondary analyses include treated analyses. We will also specify rules for handling data
and determining outcome.
Discussion: Several challenges for study design and execution can be seen in our trial, and it should generate
results that will inform and influence the practice of renal replacement therapy in critically ill patients with acute
kidney injury.
Trial registration: German Clinical Trials Register: DRKS00004367 (www.germanctr.de); 28 May 2013.
Keywords: Critically ill patients, Renal replacement therapy, Acute kidney injury, Clinical trial
Background
Acute kidney injury (AKI) is a well-recognized complica-
tion of critical illness with an important impact on mor-
bidity and mortality [1, 2]. Despite substantial advances
in our knowledge of the management of critically ill pa-
tients, mortality associated with AKI remains high [3–5].
Renal replacement therapy (RRT) causes a considerable
escalation in the complexity of treatment, has inherent
risks for adverse effects and increases cost of care for
those with severe AKI. Although RRT is a key compo-
nent of modern critical care, several fundamental princi-
ples, including the optimal timing of RRT initiation,
remain unclear [6].
Although there has been interest in the timing of RRT
initiation, a lack of consensus regarding the definition
and stages of AKI, until recently, has limited progress. In
addition, studies have used various arbitrary definitions
for ‘early’ and ‘late’ initiation instead of using classifica-
tion systems for AKI.
A retrospective study assessed the effect of timing of
initiation of RRT on outcome in patients with posttrau-
matic AKI [7]. Serum BUN served as a surrogate marker
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to determine early versus late initiation of RRT. Survival
was 20 % in the late group and 39 % in the early group
(p = 0.041). Two prospective multicentre observational
studies [8, 9] demonstrated higher mortality, longer hos-
pital stay, longer duration of RRT and higher dialysis de-
pendence in the late group. Bagshaw et al. [8] stratified
early and late by median urea and serum creatinine at
the time RRT was started and demonstrated no signifi-
cant difference between late and early initiation of RRT
using serum urea as surrogate marker (63.4 % vs. 61.4 %,
p = 0.48). When stratified by creatinine, late RRT was as-
sociated with lower mortality (53.4 % vs. 71.4 %, p <
0.0001). However, for timing relative to ICU admission,
late RRT was associated with higher mortality rates
(72.8 % vs. 59 %, p <0.001). Shiao et al. [9] divided pa-
tients into early (RIFLE-0 or -Risk) and late (RIFLE-In-
jury or -Failure) RRT by RIFLE criteria and found
significantly higher hospital mortality in the late group
(74.5 % vs. 43.1 %, p = 0.002). A multicentre observa-
tional study analyzed data on timing of initiation of RRT
based on the median BUN at the time of initiation of
RRT [10]. No significant survival benefit in patients re-
ceiving early RRT could be demonstrated (survival 59 %
late vs. 65 % early, p = 0.09). Unfortunately, these obser-
vational studies are limited to patients who had received
RRT but excluded patients with AKI that had never re-
ceived RRT. Recently, the Randomized Evaluation of
Normal versus Augmented Level of Replacement Ther-
apy (RENAL) study investigators published a subgroup
analysis of the RENAL trial testing the effect of earlier
commencement of RRT on the outcome of critically ill
patients with AKI using RIFLE-Injury as surrogate
marker [11]. Earlier initiation of RRT relative to RIFLE-
Injury AKI did not show significant graded elevations in
the risk of death with progressively delayed RRT. Re-
cently, three meta-analyses suggest that earlier initiation
of RRT in critically ill patients with AKI might be associ-
ated with a survival benefit [12–14]. However, the stud-
ies were heterogeneous and of variable quality.
All of these studies used creatinine, BUN and urine
output according to the AKI classification systems to
initiate RRT. However, these are functional markers
and none of them can predict progression of renal
injury and the need for renal replacement therapy
[15, 16]. Therefore, in earlier prospective randomized
trials some patients received RRT, although these pa-
tients might have recovered from AKI without RRT.
Lately, research on AKI has focussed on new bio-
markers for early detection of AKI and worsening of
renal function, making them applicable for initiating
RRT [17, 18]. Therefore, a prospective, randomized
trial combining functional and damage markers is
needed to provide evidence for the best timing of
RRT in critically ill patients with AKI.
Methods/design
The early versus late initiation of renal replacement
therapy in critically ill patients with acute kidney injury
(ELAIN) study is a randomized, single-centre, two-arm,
parallel group trial of different RRT implementation
strategies for critically ill patients with AKI. Institu-
tional review board approval was obtained from the
Research Ethics Committee of the Chamber of Physi-
cians Westfalen-Lippe and the Westfalian Wilhelms
University of Münster (2012-426-f-S), Germany, and
the trial is registered in the German Clinical Trials
Register (DRKS00004367). The overall study flow is
summarized in Fig. 1.
Patient population
We plan to enrol 256 adult patients (age 18–90 years)
fulfilling the inclusion criteria with written informed
consent. If the patient is unable to provide informed
consent, the legally authorized representative will be
asked and in his/her absence a declaration for inclusion
in an emergency situation is to be signed by a consultant
physician who is not involved in the study and who is
independent of the investigational team. Patient or le-
gally authorized representative informed consent will be
obtained as soon as possible. No patient will be excluded
from the study on the basis of gender, race or ethnicity.
Patients will be identified for recruitment by screening
patients receiving care in the critical care units of our
centre on a daily basis.
Inclusion criteria
All patients are eligible if they fulfill all inclusion criteria
and no exclusion criteria. The inclusion criteria are as
follows:
 Kidney Disease: Improving Global Outcomes
(KDIGO) stage 2 (two-fold increase in serum
creatinine from baseline and/or urinary output
<0.5 ml/kg/h ≥12 h) (Table 1) despite optimal
resuscitation: a) optimizing intravascular volume
(fluid resuscitation: pulmonary artery occlusion
pressure/central venous pressure of >12 mmHg,
stroke volume variation <12 % in ventilated
patients); b) optimization of cardiac index (>2.6 l/
min per square meter); c) hemodynamic
optimization (mean arterial pressure >65 mmHg);
and d) normalizing intra-abdominal pressure
(<15 mmHg);
 Plasma neutrophil gelatinase-associated lipocalin
(NGAL) >150 ng/ml;
 At least one of the following conditions: a) severe
sepsis; b) use of catecholamines (norepinephrine or
epinephrine >0.1 μg/kg/min); c) refractory fluid
overload (worsening pulmonary edema, PaO2/FiO2
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< 300 mmHg and/or fluid balance >10 % of body
weight); and d) development or progression of non-
renal organ dysfunction (Sequential Organ Failure
Assessment (SOFA) score ≥2);
 Age between 18 and 90 years; and
 Intention to provide full intensive care treatment for
at least 3 days.
Exclusion criteria
The exclusion criteria are as follows:
Fig. 1 Trial workflow. Patients will be identified for recruitment by screening all patients receiving care in the ICU on a daily basis. Before
enrolment, the fluid status is analyzed in cooperation with the attending physicians and optimized if necessary. After optimization is ensured,
informed consent is obtained and the patient will be registered by randomization. Before initiating RRT, laboratory tests will be performed and
different variables will be documented. In the ‘early’ group, RRT will be initiated immediately after randomization, whereas initiation of RRT in the
‘late’ group will be started only after reaching stage 3 of the KDIGO classification and/or if absolute indications for RRT are present. Patients
randomized to ‘late’ but never reaching stage 3 will remain in the ‘late’ group for purposes of analysis. Laboratory tests will be analyzed and
variables relevant for the assessment of illness severity will be recorded on day 1 to day 21, day 28, day 60, day 90 and 1 year
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 Pre-existing chronic kidney disease not requiring
RRT (GFR <30 ml/min);
 Previous RRT;
 AKI caused by permanent occlusion or surgical
lesion of the renal artery;
 AKI caused by glomerulonephritis, interstitial
nephritis or vasculitis;
 AKI caused by postrenal obstruction;
 Hemolytic-uremic syndrome/thrombotic
thrombocytopenic purpura;
 Pregnancy;
 Prior kidney transplantation;
 Hepatorenal syndrome;
 AIDS with a CD4 count of <0.05 x 10E/l;
 Hematologic malignancy with neutrophils of <0.05 x
10E/l;
 No hemofiltration machine free for use at the
moment of inclusion; and
 Participation in another interventional clinical trial.
Enrolment
Enrolment began in August 2013. Prior to being ran-
domized into the study, the trial coordinators obtain
consent for participation in the study (see Ethics and
consent). Assuming all inclusion criteria are fulfilled and
no exclusion criteria are met, each patient receives a
study identification number and treatment allocation at
enrolment. Patients are randomized in a 1:1 ratio to one
of the two treatment arms using a computerized system.
Randomization is stratified by SOFA Cardiovascular
organ Failure Score (0–2 vs. 3–4) and by the presence or
absence of oliguria. The randomization day is day 0.
Treatment arms
Early initiation of RRT will be initiated at stage 2 of the
KDIGO classification within 8 hours:
 Urine output <0.5 ml/kg/h for ≥12 h; and/or
 Two-fold increase of the serum creatinine level
compared to the baseline value.
Late initiation of RRT will be initiated when stage 3 of
the KDIGO classification (not later than 12 hours after
achieving stage 3) is achieved:
 Urine output <0.3 ml/kg/h for ≥24 h; and/or
 > Three-fold increase of the serum creatinine level
compared to the baseline value; and/or
 Serum creatinine of ≥4 mg/dl with an acute increase
of at least 0.5 mg/dl within 48 hours.
Or if any of the following absolute indications for RRT
are present:
 Urea serum levels >100 mg/dl;
 Potassium serum levels >6 mmol/l and/or ECG
abnormalities;
 Magnesium serum levels >4 mmol/l;
 Urine production <200 ml/12 h or anuria (without
diuretics, according to the KDIGO
recommendations); and
 Organ edema in the presence of AKI resistant to
diuretic treatment (one attempt with loop diuretics
prior to randomization).
After enrolment, ELAIN investigators are responsible
for the catheter insertion and the initiation of RRT (see
Additional file 1). Daily visits will be performed to en-
sure adherence to the protocol. Hemodynamic, pulmon-
ary, inflammation, renal and laboratory data will be
documented. Education to ensure proper implementa-
tion of the study protocol was done prior to starting en-
rolment. Project manager and trial investigators conduct
monthly conferences to monitor all aspects of the
protocol.
Patient management
All patients receive standard intensive care therapy. As
no pharmacological therapy for AKI exists, the manage-
ment of AKI remains primarily supportive, with renal re-
placement therapy serving as a cornerstone of therapy
for patients with severe kidney injury. None of the pa-
tients in both groups (‘early’ and ‘late’ groups) are ex-
posed to additional risks.
The patient’s primary physicians determine the re-
mainder of patient management, consistent with estab-
lished best practices for the management of critically ill
patients (e.g. use of diuretics, application of fluids).
Measuring central venous pressure and cardiac output is
performed in all patients. These co-interventions are not
standardized, but they are recorded and will be analyzed
after finishing the trail. As this is a prospective random-
ized trial, there should not be any differences between
the groups. Further treatment rules are described in
Additional file 1.
Table 1 Staging of acute kidney injury using KDIGO
recommendations
Stage Serum creatinine criteria Urinary output criteria
1 Serum creatinine x 1.5
or serum creatinine rise
of 0.3 mg/dl in 48 h
<0.5 ml/kg/h for 6 h
2 Serum creatinine x 2 <0.5 ml/kg/h for 12 h
3 Serum creatinine x 3
or serum creatinine ≥4
mg/dl or renal replacement
therapy
<0.3 ml/kg/h for 24 h
or anuria for 12 h
KDIGO, Kidney Disease: Improving Global Outcomes [6]
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Outcomes
The primary endpoint is overall survival in a 90-day
follow-up period. If the difference in overall survival is
significant, the treatment effect will be estimated by
means of the 90-day all-cause mortality rate in both
treatment groups.
Secondary outcomes include:
 Overall survival in a 28-day and 60-day follow-up
period;
 Overall survival in a 1-year follow-up period;
 Clinical evidence of organ dysfunction (daily SOFA
scores while in the ICU);
 Recovery of renal function as defined in the KDIGO
guidelines [6];
 Requirement of haemodialysis after day 28 and day
60;
 Duration of renal support;
 ICU and hospital length of stay; and
 Markers of inflammation, oxidative stress, cellular
hypoxia and coagulation.
Ethics and consent
The present trial protocol is performed in accordance
with the Declaration of Helsinki (version October 2008;
49th General Assembly of the World Medical Associ-
ation, Somerset West, Republic of South Africa) and ap-
proved by the institutional review board from the
Research Ethics Committee of the Chamber of Physi-
cians Westfalen-Lippe and the Westfalian Wilhelms
University of Münster.
Data collection will be performed pseudonymously
and the patient’s name will not appear on any case re-
port form (CRF) or in any other trial document. All data
will be kept confidential. Consent procedures follow
local requirements, as approved by the ethics committee
of the University of Münster. The treating investigator
will inform the patient about the nature of the trial, its
aims, expected advantages as well as possible risks. Writ-
ten informed consent will be obtained from eligible pa-
tients and in case of patient incapacity by the legally
authorized representative (see Additional file 2). In case
of an emergency situation a consultant physician who is
independent of the investigational team will be involved.
Once the participant regains capacity or the legally au-
thorized representative is available, he/she will be asked
to affirm or withdraw consent.
Objectives and aims
Aim 1
To compare the clinical efficacy between early and late
initiation of renal replacement therapy in critically ill pa-
tients with AKI, we are testing the following:
 Hypothesis I: early initiation of renal replacement
therapy in the treatment of critically ill patients with
AKI will reduce mortality at 90 days compared to
late initiation.
Aim 2
To understand the mechanisms of illness and recovery
and how the RRT implementation strategies affect them,
we are testing the following:
 Hypothesis II: early and late RRT are associated with
differences in the expression of markers of illness
and recovery.
Aim 3
We aim to assess the costs and cost-effectiveness of both
strategies.
Statistical analysis
Statistical analyses will be performed according to the
principles of the ICH guideline E9 ‘Statistical principles
for clinical trials’ [19] using standard statistical software
(IBM SPSS Statistics, Armonk, NY, USA).
Power and sample size
Power calculations are performed based on the primary
endpoint, i.e. the overall survival in a 90-day follow-up
period. The primary efficacy analysis is intended to test
whether early versus late initiation of RRT in intensive
care patients with AKI results in different overall sur-
vival in a 90-day follow-up period.
An adaptive design based on a group sequential plan
according to O’Brien and Fleming with one interim ana-
lysis and a global (two-sided) significance level α = 0.05
is applied (see below). The expected 90-day mortality
rate in the control group with late initiation of RRT is
55 % (based on literature research [7–10, 20–24]). Dif-
ferences between treatment groups are to be detected
with a power of 80 %, if the 90-day mortality rate in the
experimental intervention group with early initiation of
RRT is 37 % or smaller. The expected treatment effect of
18 % is calculated on the mortality differences between
the early and late groups resulting from the studies of
our literature research [7–10, 20–24] (see Additional file
3). The interim analysis is conducted at the time when
half of the total number of deaths has been observed (in-
formation rate 0.5). Follow-up of each patient will be
90 days. Resulting from these considerations, the interim
analysis is performed after 53 deaths have been observed
across both treatment groups. The final analysis is
planned to be performed after 106 deaths have been ob-
served in total across both treatment groups, i.e. assum-
ing an average of 46 % mortality rate in the 90-day
follow-up period, a total number of 106/0.46 = 230
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patients across both treatment groups is included in the
final analysis. This corresponds to 256 recruited patients,
if an expected number of 10 % of recruited patients is
assumed to be lost to follow-up and in the worst case
has completely non-evaluable data. Power calculations
are to be performed based on a two-sided inverse nor-
mal log-rank test [25], using ADDPLAN software
(ICON, Dublin, Ireland).
Interim analysis
A group sequential plan according to O’Brien and Fleming
with one interim analysis is established. In order to main-
tain a global significance level alpha = 0.05, the interim
and the final analysis are performed on local significance
levels of 0.0052 and 0.0480, respectively. Based on the
group sequential plan, an adaptive design is applied, that
admits two possible design changes after the interim ana-
lysis: i) the number of deaths of the final analysis will be
re-calculated applying the inverse normal method [26];
and ii) the schedule and the number of further interim
analyses may be modified applying the conditional rejec-
tion error probability (CREP) principle [27, 28].
i) Re-calculation of the number of deaths of the final analysis
applying the inverse normal method
The basic idea of the inverse normal method is to trans-
form the p values of successive stages of a multistage
trial to normally distributed test statistics that can be
processed using group sequential methods. In particular,
let p1 and p2 denote the p values of the interim and final
statistical analysis, respectively. Then in the final analysis
the null hypothesis is rejected if:
C p1; p2ð Þ :¼ 1−∅
ﬃﬃﬃ
1
2
r
Än ∅−1 1−p1ð Þ þ
ﬃﬃﬃ
1
2
r
Än ∅−1 1−p2ð Þ
" #
≤αc:
The term αc is determined so that the overall type I
error is controlled.
Interim data on the primary outcome comprise the
treatment arm, the date of randomization, a status indi-
cator of death within 90 days post-randomization, as
well as the data of death or last follow-up. Using these
data the conditional power of a significant final result is
calculated: a) based on the observed hazard ratio of early
versus late initiation of RRT at the time of the interim
analysis; as well as b) based on the originally assumed
hazard ratio. The number of deaths of the final analysis
is determined as follows:
 If the originally planned number of deaths of the
final analysis yields a conditional power larger than
(1 − βupper
cond ) calculated according to both approaches
a) and b), then the originally planned number of
deaths is kept unchanged.
 If in one or both of the two approaches a) and b)
the conditional power is between (1 − βlower
cond ) and
(1 − βupper
cond ), then the number of deaths of the
final analysis is increased, so that in both
approaches a) and b) the conditional power is at
least equal to (1 − βupper
cond ). In any case, however,
the maximum number of additionally recruited
patients in the second stage of the trial is
restricted to an upper limit of 350 patients.
 If in both approaches a) and b) the conditional
power is lower than (1 − βlower
cond ), then no further
patient is recruited and the study is stopped.
The values (1 − βlower
cond ) and (1 − βupper
cond ) are kept confi-
dential in order to preserve the integrity of the trial.
Otherwise, if the number of additionally recruited pa-
tients in the second stage of the trial is announced, this
information could be used to disclose the results of the
interim analysis.
ii) Modification of the schedule and the number of further
interim analyses applying the CREP principle
Upon inspection of interim results beyond the re-
calculation of the number of deaths, further possible de-
sign changes will be performed, i.e. a modification of the
schedule and the number of further interim analyses.
These changes will be done according to the CREP
method [27, 28]. The CREP principle is a general
method used in adaptive clinical trials. In an interim
analysis based on current data, the CREP is calculated,
that is the conditional probability that in the final ana-
lysis a significant result will be reached, under the initial
study design, and under the null hypothesis, conditional
on the information that is available so far. Denote this
probability CREP0. The CREP principle then suggests
that after the interim analysis a completely different de-
sign may be chosen – if the new design is constructed
so that it provides the same conditional rejection error
probability CREP0 as the initial design.
Modifications to the protocol will be made only in the
form of written amendments and with the agreement of
the study committee. The respective ethics committees
will be informed of the modifications and patient infor-
mation will be changed according to the modifications
of the protocol.
Suppose, for example, that upon the inspection of in-
terim results according to i) it is decided to continue to
follow-up patients and to perform the final analysis at
the time when 151 deaths have been observed in total
across both treatment groups. Moreover, suppose that
the calculated conditional rejection error probability at
the time of the interim analysis amounts CREP0 = 0.04.
In this case it may be decided to introduce another in-
terim analysis before the final analysis is performed.
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Therefore, a new group sequential plan is established
and implemented at the time of the (first) interim ana-
lysis. The new group sequential plan consists of one
(further) interim analysis before the final analysis is per-
formed after 151 deaths have been observed, and main-
tains a (two-sided) significance level alpha = CREP0 =
0.04. Concretely, the new group sequential plan may be
established according to Pocock, so that the second in-
terim analysis is performed after 53 + 49 = 102 deaths
have been observed in total, and both the second interim
and the final analysis are performed on local significance
levels of 0.0233, respectively.
Primary outcome analyses
The primary efficacy analysis will include all randomized
patients (full analysis set) and will be performed accord-
ing to the intention-to-treat principle, i.e. all patients are
analyzed in the group to which they were randomized
(Fig. 2). The effect of early initiation of RRT versus late
initiation of RRT on overall survival in a 90-day follow-
up period will be assessed by comparing the randomized
groups with a (two-sided) inverse normal log-rank test
[21]. If the difference in overall survival is significant,
the treatment effect will be estimated by means of the
90-day all-cause mortality rate in both treatment groups.
The primary intention-to-treat analysis of the primary
outcome provides confirmatory statistical evidence.
Beyond the above primary analysis, the following pre-
specified sensitivity analyses will be performed (see
Fig. 2). In per-protocol analyses only patients without
major protocol violations are included (see Fig. 3); in
particular, patients are included only if they complete
90-day follow-up (complete case analysis). Using these
data two kinds of analysis are performed in order to ad-
dress two different questions.
 In a first approach, the primary outcome is
evaluated (overall survival in a 90-day follow-up
period) using a two-sided inverse normal log-rank
test [21]. The only difference to the primary analysis
is that a per-protocol approach is pursued instead of
an intention-to-treat analysis.
 In a second approach, data are reduced from the
original primary outcome to the binary outcome
‘90-day mortality from all causes’. The binary
outcome is created in order to provide
comparability to other published study results. It is
evaluated using a two-sided Chi-squared test.
Further statistical analyses of the primary outcome will
be performed in order to address the fact that study pa-
tients have different risk profiles at the time of RRT ini-
tiation. The efficacy of the experimental and the control
treatment may differ depending on the patient’s risk pro-
file. For example ‘high risk’ patients may benefit from
experimental treatment with early initiation of RRT sub-
stantially compared to control treatment, whereas in
‘low risk’ patients the ‘late’ approach may be superior. In
order to address these questions, multivariable statistical
analyses will be performed using Cox regression. Overall
survival is modelled as a function of baseline risk (deter-
mined by pre-randomization baseline data such as the
patient’s age, Acute Physiology and Chronic Health
Evaluation (APACHE) score and SOFA score, as well as
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Fig. 2 Statistical analysis with intention-to-treat principle. All recruited ELAIN patients randomly allocated to the early or late group will be considered
for intention-to-treat. Patients with protocol violation will be included in the analysis to gain a representative result of the daily practice.
Protocol violation is defined as: subjects in the early group who did not receive RRT in the early phase of AKI (KDIGO stage 2); and
subjects in the late group who did not receive RRT, although KDIGO stage 3 was achieved and patients were lost to follow-up
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the baseline medical condition, i.e. severe sepsis/use of
catecholamines/refractory fluid overload/development or
progression of non-renal organ dysfunction), RRT treat-
ment and the interaction of baseline risk and RRT treat-
ment. In three different model approaches, RRT treatment
is expressed in terms of: i) a time-dependent covariate that
impacts survival starting with the time of RRT initiation;
ii) the randomized treatment group; and iii) the time to
initiation of RRT.
Secondary and tertiary outcome analyses
Statistical analysis of the pre-specified secondary end-
points will be performed with descriptive and inductive
statistical methods. Survival data will be described by
Kaplan–Meier plots and survival distributions will be
compared using the log-rank test. Ordinal scores and
non-normally distributed metric measures will be ana-
lyzed using non-parametric methods, including calcula-
tion of the median and quartiles and comparison of
distributions using the Mann–Whitney U test. In case of
normally distributed metric measures parametric
methods will be used, including calculation of the mean
and standard deviation and comparison of distributions
using Student’s t-test. Binary data will be presented by
contingency tables and rates will be compared using the
Chi-squared test. Secondary and tertiary outcome ana-
lyses are considered not to be confirmatory. The p
values are regarded noticeable in case p ≤0.05. No ad-
justment for multiple testing will be performed. There-
fore, an overall significance level is not determined and
cannot be calculated.
Additional exploratory analyses will include model-
based analyses, subgroup analyses and safety analyses. In
safety analyses, all study patients will be included (safety
population).
Trial management
Protocol adherence
Initiation and close-out visits will be performed. The
trial site will be regularly visited during recruitment and
follow-up. The scope of these visits is to check compli-
ance of the trial site with the study protocol and ‘good
clinical practice’ rules. For all patients, the informed
consent documents will be checked. In addition, source
data verification of the key data (eligibility criteria, inter-
vention, outcome measures) will be performed routinely
in a random sample of 50 % of the patients. Monitoring
will follow the standard operating procedure (SOP)
based on the Technologie- und Methodenplattform für
die vernetzte medizinische Forschung e.V. (TMF)-SOPs.
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Fig. 3 Statistical analysis with per-protocol principle. Patients with protocol violation will be excluded in the analysis to analyze the effect of both
treatment arms. Protocol violation is defined as: subjects in the early group who did not receive RRT in the early phase of AKI (KDIGO stage 2);
and subjects in the late group who did not receive RRT, although KDIGO stage 3 was achieved
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Data collection and management
All trial-related processes will follow the SOPs. Accord-
ing to the SOPs, key documents and processes are sub-
ject to internal review. The data will be collected on
paper CRFs and stored at the Department of
Anesthesiology, Intensive Care and Pain Medicine at the
University of Münster. Monitoring will include a timely
query management process based on consistency and
plausibility checks, combined with a dunning process for
missing documentation.
Safety
The Executive Committee is the management and
decision-making body for the operational aspects of the
study and will monitor the performance of the medical
center and the quality of data collected. The Executive
Committee will formulate publication plans and will
oversee the publication and presentation of all data from
the study. The Committee must grant permission before
any study data may be used for presentation or
publication.
Discussion
The decision to start RRT in critically ill patients with
severe AKI can depend on numerous factors and is,
therefore, a complex process [8]. Timing of RRT has
been difficult to study and has shown considerable vari-
ation between clinicians and institutions [29]. As a con-
sequence, the question of the optimal timing of the
initiation of RRT has not been solved yet [8–11, 13, 14].
Theoretically, initiation of RRT before the onset of severe
AKI might influence patient outcomes. Specifically, early
RRT might attenuate kidney-specific and non-kidney
organ injury from acidemia, uremia, fluid overload and
systemic inflammation, and potentially translate into im-
proved survival and earlier recovery of kidney function
[17, 18]. The results of three meta-analyses already
showed that the early initiation of RRT might have a po-
tential survival benefit for critically ill patients with AKI
[12–14]. However, on the contrary, early initiation of RRT
might involve patients who would recover renal function
with conservative treatment alone. Consequently, this
would result in unnecessary RRT with potential risks asso-
ciated with RRT, raising an important ethical issue.
The ELAIN trial is a prospective randomized trial with
the objective to analyze the influence of RRT timing on
survival of critically ill patients with AKI. There are
some aspects of the trial protocol that bear specific
mention.
The study design contains a specific protocol that
tends to minimize unnecessary RRT trying to prevent
patients from avoidable RRT-related risks and improve
patients’ outcome. In 2012, the KDIGO group published
the KDIGO criteria for diagnosing AKI [6]. It has been
shown that only 20 % of patients who develop KDIGO
stage 2 progress to KDIGO stage 3 [30]. Sepsis and other
severe conditions (e.g. hemodynamic instability mani-
fested by hypotension requiring vasopressor support, re-
fractory fluid overload) have been shown to be
important risk factors for developing dialysis-dependent
AKI [31, 32]. Therefore, the inclusion criteria chosen for
the ELAIN trial were selected to identify patients who
are at high risk for the need of RRT. In addition, we
chose a biomarker-based model for the detection of pa-
tients with worsening AKI, because previous studies
demonstrated that biomarkers can be used for identify-
ing potential aggravation [16]. By using this patient-
enrichment strategy, we excluded patients whom subse-
quently recovered from AKI spontaneously without re-
quiring RRT. Plasma NGAL is one of the most studied
biomarkers in the field of AKI. The diagnostic value for
the detection of AKI might be controversial [33, 34] but
for the need of RRT in critically ill patients it has been
demonstrated as a good predictor [35, 36]. Thus, to re-
duce the risk of unnecessary RRT, we only include pa-
tients with KDIGO stage 2, concomitant disorders and
elevated NGAL values [35].
Nevertheless, the ELAIN trial has some limitations.
The power calculation is based on data published a
long time ago. Although the mortality of dialysis-
dependent AKI decreased over the last 20 years [37],
the mortality is still unacceptably high. A recently
published meta-analysis regarding the initiation of
renal replacement therapy analyzed 15 trials published
between 1985 and 2011 and the authors showed that
the overall 28-day mortality across the 15 trials was
55 % [13]. Although this study included older studies,
a recently published trial investigating critically ill pa-
tients with a dialysis-dependent AKI also demon-
strated that the 60-day all-cause mortality in critically
ill patients with a dialysis-dependent AKI is 52 %
[38]. Another limitation of the study is that we in-
clude critically ill patients with AKI stratified by
hemodynamic SOFA score and urinary output accept-
ing heterogeneity due to the inclusion of septic and
non-septic patients. The pathophysiology of septic
AKI is unique resulting in differences in clinical out-
comes and responses to renal replacement therapy
compared to non-septic patients [31]. But implement-
ing a specific protocol with homogenous criteria for
the diagnosis of critical illness and acute kidney injury
combined with biomarkers is the first step to filling
an important knowledge gap. Another limitation of
such a trial design is that the investigators cannot be
blinded and consequently there is a risk of contamin-
ation or unequal prescription of co-interventions.
However, we adequately take this into account by a
clear monitoring of all interventions.
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Several studies investigating the timing of continuous
RRT in critically ill patients used the time from
randomization to commencement of continuous RRT to
define ‘early’ and ‘late’ [8, 39]. In our trial we use the se-
verity of AKI based on the KDIGO criteria to define
‘early’ and ‘late’ initiation of continuous RRT. The initi-
ation of RRT represents an escalation in the level of care
and is associated with certain risks. In the past, it has
been shown that the Acute Kidney Injury Network
(AKIN) criteria alone cannot predict the progression of
the severity of AKI [30]. But the biomarker NGAL has
been shown to predict the progression of the severity of
AKI [40, 41] and the need for RRT in critically ill pa-
tients [15, 35]. Therefore, we combine the KDIGO cri-
teria with clinical risk factors and NGAL to increase the
probability that we only include patients with severe
AKI who subsequently need RRT and exclude patients
who spontaneously recover from AKI. This might not be
a validated approach, but the study results will show
whether the combination of these factors can identify
patients who subsequently develop a dialysis-dependent
AKI.
The ELAIN trial is the first randomized controlled
trial that includes a biomarker in a specific protocol plan
to detect patients who will develop a severe, dialysis-
dependent AKI. The results might be a significant con-
tribution to the therapy of critically ill patients with
acute kidney injury.
Trial status
Recruitment is active.
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